• 24 June, 2025

Suven grants exclusive license to Taro Pharmaceuticals

March 07, 2014 | Friday | News | By BioSpectrum Bureau

Suven grants exclusive license to Taro Pharmaceuticals

Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.

In this regard, Taro will pay Suven a royalty and the arrangement is effective until April 2028, unless otherwise terminated.

 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is India’s Integrated DigiTech targeting Affordable Healthcare Access?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy